GlassScriptPhysician profile
Shailesh Basani
NPI 1629269972
$1,635.16
in general payments reported to CMS, 2019-2025
21 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $37.98 · 2021: $260 · 2022: $318 · 2023: $251 · 2024: $191 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811 · Education: $4.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.61 |
| Education | $4.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $213.20 | 2021-2025 | Thiola |
| Mallinckrodt Hospital Products INC. | $207.15 | 2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $196.68 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $154.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $128.65 | 2019-2023 | Farxiga |
| Aurinia Pharma U.S., INC. | $89.83 | 2021-2022 | |
| Vifor Pharma, INC. | $86.63 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $76.98 | 2021-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $69.62 | 2021-2024 | |
| Lilly USA, LLC | $52.89 | 2019 | |
| Calliditas Therapeutics US INC. | $52.13 | 2022-2025 | Tarpeyo |
| Scpharmaceuticals INC. | $51.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $47.88 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.08 | 2019 | |
| Amgen INC. | $33.32 | 2021-2025 | Krystexxa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.64 | 2019 | |
| Glaxosmithkline, LLC. | $27.32 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $25.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.53 | 2020 | |
| Akebia Therapeutics INC | $14.20 | 2022 | |
| Novo Nordisk INC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailesh Basani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.